drugset / Trial / NCT06981637
Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Phase 2
Recruiting
81 enrolled
National Health Research Institutes, Taiwan
Chang Gung Memorial Hospital · collabChina Medical University Hospital · collabKaohsiung Medical University Chung-Ho Memorial Hospital · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collabTaipei Veterans General Hospital, Taiwan · collabTri-Service General Hospital (TSGH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Timeline
- Start
- 2025-12-31
- Primary completion
- 2028-07-31
- Completion
- 2029-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegylated liposomal doxorubicin | Unknown | 40 mg/m2 | — |